At the 2025 World Conference on Lung Health, we, alongside EPCON, introduced a transformative solution in the global tuberculosis (TB) response: CAD4TB+, the first AI-powered platform to integrate TB detection, nationwide surveillance, and predictive analytics in a single system. This partnership marks a major step toward closing the TB detection gap that continues to drive transmission, especially in high-burden countries.
“TB remains one of the world’s deadliest infectious diseases, and early and efficient detection in vulnerable and hard-to-reach communities is essential,” said Guido Geerts, President and CEO of Delft Imaging. “By seamlessly integrating imaging data with surveillance intelligence, CAD4TB+ transforms every screening into an insight that helps close the detection gap and accelerate the path toward TB elimination.”
Detection meets intelligence
CAD4TB+ combines our well-established AI chest X-ray software with EPCON’s Epi-control platform, creating a powerful tool for national TB programs. The platform not only enables the detection of TB at the individual level but also connects that data to national systems for real-time surveillance, analysis, and response.
“By turning every chest X-ray into a meaningful data point, we empower programs to act with precision and strengthen surveillance systems. Together, we’re building stronger public health systems powered by data and AI.”
Caroline Van Cauwelaert, CEO of EPCON
A predictive advantage
CAD4TB+ goes beyond identifying active cases. Its predictive analytics module uses historical and real-time data to anticipate future TB hotspots. This enables health authorities to deploy resources more efficiently and respond before outbreaks escalate.
In Nigeria, predictive mapping guided by Epi-control resulted in up to 103 percent higher TB positivity in targeted areas. In South Africa, data-driven outreach reduced the cost per TB case from $1,748 to $437. These results show how the integration of diagnostics and surveillance can lead to greater efficiency and impact.
Built on proven results
The foundation of CAD4TB+ is CAD4TB, which has already screened over 55 million people in more than 90 countries. Supported by over 120 scientific publications, CAD4TB remains the most validated AI solution for TB detection.
CAD4TB+ addresses a critical challenge. According to the WHO, global TB incidence is decreasing at only 2 percent per year, far below the 10 percent annual reduction needed to reach the End TB goals. Solutions like CAD4TB+ offer the integrated intelligence and field-based effectiveness required to change that trajectory.
